Cited by 456Metabolism, Diabetes, and CancerPeroxisome Proliferator-Activated ReceptorsAdipose Tissue and Metabolism

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome

Ruderman, Neil, Prentki, Marc·2004·Nature Reviews Drug Discovery

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd1344

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 168 references

Research works printed but not linked: 4

  1. Kraegen, E. W. et al. Insulin resistance induced by glucose infusion is associated temporally with reduced muscle and liver AMPK activity. Diabetes 52, A330 (2003).
  2. Ido, Y. et al. The AMP-kinase (AMPK) activator, AICAR, inhibits the increase in oxidative stress induced by hyperglycemia and palmitate. Diabetes 51, A396 (2002).
  3. Ido, Y., Yagihashi, N., Cacicedo, J. M., Ruderman, N. B. AMP-kinase activation prevents TNF-α induced ICAM expression by inhibiting NF-κB transactivation but not by inhibiting their translocation or DNA-binding. Diabetes 51, A458 (2002).
  4. Sbraccia, P. et al. Rosiglitazone treatment improves insulin sensitivity in lipodystrophic patients with mandibuloacral displasia. Diabetes 52, A1 (2003). · DOI · Paper page

Cited by

Sorted by citations

Items 101–200 of 456

Metadata

Authors
Ruderman, N., & Prentki, M.
Affiliations
  • Boston University (US)
  • Centre Hospitalier de l’Université de Montréal (CA)
Venue
Nature Reviews Drug Discovery
Published
2004-04-01
Volume
3
Issue
4
Pages
340-351
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1983336199
Cited by
451
References
168
Citations by year
2026: 4 · 2025: 13 · 2024: 12 · 2023: 11 · 2022: 23 · 2021: 17 · 2020: 19 · 2019: 21 · 2018: 13 · 2017: 22 · 2016: 19 · 2015: 14 · 2014: 27 · 2013: 22 · 2012: 21
FWCI
2.30
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
AMPK, malonyl-CoA, metabolic syndrome, insulin resistance, obesity, fatty acid metabolism, ectopic fat deposition, AMPK activators, therapeutic target, type 2 diabetes, atherosclerosis
MeSH terms
Adenylate Kinase, Animals, Fatty Acids, Humans, Malonyl Coenzyme A, Signal Transduction, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review